Stephen D. Miller

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

S. Ou, C. Lengauer, Wei Hu, 2018, Cancer discovery.

A precision therapy against cancers driven by KIT/PDGFRA mutations

A. Gardino, N. Lydon, M. Heinrich, 2017, Science Translational Medicine.

Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain.

J. Fletcher, E. Wardelmann, M. Heinrich, 2020, Cancer Discovery.

Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma

Seung‐Mo Hong, Deokhoon Kim, E. Choi, 2017, Oncotarget.